Jul 17, 2017
Cardiff, UK – 17th July 2017 – EKF Diagnostics, the global in vitro diagnostics company, has published a guide to ‘Diabetes and HbA1c testing’ which can be found at EKF’s new Diabetes Portal (www.ekfdiagnostics.com/diabetes-portal.html).
Read More
Jun 30, 2017
DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan’s Fluent® Laboratory Automation Solution as its nucleic acid extraction platform. The new platform will be used in combination with the DiaSorin Liaison® MDX PCR system to provide the customer with a complete sample to result system for molecular diagnostics.
Read More
Jun 26, 2017
Investment will help commercialize Cytox’s services for testing for Alzheimer’s disease and grow Cytox as a leader in this area. 15 June 2017, Oxford & Alderley Park, UK. Cytox, an emerging precision medicine leader providing genetic testing for Alzheimer’s disease, has announced that it has raised £2.6m (approx $3.3m) to fund the commercial launch and international roll out of its comprehensive testing service.
Read More
Jun 21, 2017
Cardiff, UK – 21st June 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces that a recent study has confirmed that its Quo-Test® A1c point-of-care testing (POCT) analyzer shows comparable performance to a lab-based HPLC system for the measurement of glycated hemoglobin (HbA1c).
Read More
Jun 21, 2017
The TOPRA Annual Symposium is the largest forum for European regulatory professionals to meet up, discuss current regulatory issues and debate future plans for regulation.
Read More
Jun 09, 2017
SYDNEY, AUSTRALIA -- 05/06/17 -- SpeeDx Pty, Ltd. today announced an agreement with Cepheid for distribution of its PlexPCRTM and ResistancePlusTM molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the UK, will increase coverage for the market-leading ResistancePlus MG test, the first CE-IVD test for Mycoplasma genitalium to combine detection with testing for azithromycin resistance.
Read More
Jun 07, 2017
Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform London (UK) / Mechelen (Belgium), 7 June 2017 – MRC Technology (‘MRCT’), a medical research charity, and Biocartis Group NV (‘Biocartis’ or the ‘Company’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced a partnership to develop selected molecular diagnostic tests for use on Biocartis’ fully automated Idylla™ platform. MRCT aims ...
Read More
Jun 06, 2017
BBI Solutions, in partnership with Merck and Kinematic Automation, is hosting a lateral flow seminar designed to provide a practical insight into lateral flow test development. Taking place from the 6th to the 8th of June at the Fota Island Resort in Cork, Ireland, this event is aimed at industry professionals, and will cover various aspects of assay development and commercialisation, as well as offering a hands-on experience in test design.
Read More
Jun 02, 2017
BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity of cell culture transferrin production by up to 40%.
Read More
May 25, 2017
Oxford, UK – 25 May 2017. Oxford Gene Technology (OGT), The Molecular Genetics Company, has made several advances in hybridisation-based target enrichment protocols that now enable researchers to prepare samples for sequencing in just one day. Researchers can now access the high-quality results of hybridisation-based targeted sequencing with a speed comparable to that of amplicon-based approaches.
Read More
Page 11 of 13 [11]